Abstract Submission & Guidelines

Abstract Submission & Guidelines

Submit your research to the foremost international platform for Technologies & Treatments in Diabetes

Extended Abstract submission deadline: 22 October 2019

View the Abstract Topics

Abstract Submission

KEY DATES

Abstract Submission Opens18 June 2019
Abstract Submission Deadline7 October 2019 Midnight CET
Extended Abstract Submission Deadline22 October 2019 Midnight CET
Abstract Notification*End of November 2019

*Note all efforts are made to send notifications by the planned date. Should there be any delays with the selection process, revised dates will be posted here

PRESENTATION TYPES AVAILABLE:

ORAL – refers to abstracts accepted for oral presentation at the podium in dedicated Oral Presentation Sessions.
E-POSTER – electronic poster presentation on large screens in the Exhibition area to be viewed during the Conference.
E-POSTER DISCUSSION – refers to abstracts accepted for E-Poster Presentation, which will be assigned by the Abstract Review Committee, to be presented on large screens in the Exhibition Area at dedicated E-Poster sessions during break times.
E-Poster presenters who register by the early bird registration deadline will also be eligible to present a paper Poster at the Conference. Additional information will be sent to the submitters in due course.
All accepted abstracts will be published in the peer-reviewed journal Diabetes Technology & Therapeutics, published by Mary Ann Liebert, Inc., Publishers.
The Journal is indexed in PubMed.
Further information can be found here.

RULES FOR SUBMISSION

Please read the submission rules before submitting an abstract.

  • Abstracts must be submitted online via the website only.
    ABSTRACTS SUBMITTED BY EMAIL WILL NOT BE ACCEPTED.
  • Presentation Type: Abstracts may be submitted for oral or e-Poster. Late breaking submission will be submitted ONLY for e-Poster.
    The Scientific Committee will determine whether the abstract will be accepted for presentation, with consideration given to the author’s preference.
  • Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.

Limitations

  • The same person may submit up to 5 abstracts regardless of presenting author.
  • The same person may serve as presenting author on up to 3 abstracts.
  • Presenting authors must be registered participants. Only abstracts of authors who have paid their registration fees by the Early Registration Deadline: 4 December 2019 will be scheduled for presentation and included for publication.
  • Submission of an abstract acknowledges your acceptance for the abstract to be published in the official Conference publications.
  • The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
  • E-Poster presenters who register by the early bird registration deadline will also be eligible to present a paper Poster at the Conference. Additional information will be sent to the submitters in due course.
  • All accepted abstracts will be published in the peer-reviewed journal Diabetes Technology & Therapeutics, published by Mary Ann Liebert, Inc., Publishers. The Journal is indexed in PubMed.
  • Abstracts must be submitted in English.
    All abstracts should be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university specific publications office (or other similar facility) or by a copy editor, prior to submission.
  • Disclosure of Conflicts of Interest: Abstract submitters will be required to disclose any conflict of interests in the submission form.
  • Instructions for preparation of presentations will be made available on the conference website.

GUIDELINES FOR SUBMISSION

Before you begin, please prepare the following information:

  • Presenting author’s contact details:
    -Full first and family name(s)
    – Email address
    – Affiliation details: department, institution / hospital, city state (if relevant), Country
    – Phone number
  • Author and co-authors’ details
  • Preferred Presentation type: Oral Presentation/ e-Poster
  • Abstract title – must be in UPPER CASE and limited to 25 words. Please submit symbols as words.
  • Abstract text – limited to 250 words including acknowledgements.

(Please Note: word count is affected when graphs/tables are included).

  • Abstract topic– select the abstract topic per the list of topics.
  • Images– The maximum file size of each image is 500 KB. The maximum pixel size of the graph/image is 600(w) x 800(h) pixel. You may upload images in JPG, GIF or PNG format.
  • Abstracts should clearly state:
    Background and aims
    Methods
    Results
    Conclusions 
  • Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word the first time it appears.
  • Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content.
  • Submissions may not contain patient names, hospital ID numbers or other identifying information.
  • The submission form does not allow you to store your abstract as a draft.
  • Click on the SUBMIT button at the end of the process in order to save your abstract. You may log in to the system later to make changes to your abstract, up to the submission deadline. After the deadline, changes will not be possible.
  • You will receive an abstract reference number via email after you have submitted your abstract. Please refer to this abstract number in all correspondence regarding the abstract.
  • Please contact us if you have not received confirmation that your abstract has been submitted.
  • Please do not submit multiple copies of the same abstract.

ABSTRACT SUBMITTERS’ DECLARATION

During abstract submission you will be asked to confirm that you agree to the following:

  1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published as submitted.
  2. Submission of the abstract constitutes the consent of all authors to publication (e.g. Conference website, programs, other promotions, etc.)
  3. The Abstract Submitter warrants and represents that no part of the information and content provided by him/her (Hereafter: the “Content“) to ATTD 2020 and Kenes International (Hereafter: the “Organizers“), nor the publication of any such Content by the Organizers, on the internet or otherwise infringes any third party rights, including but not limited to privacy rights and/or intellectual property rights.
  4. The Abstract Submitter grants the Organizers a copyright license to reproduce, publish, translate, distribute, and display the text of the Content on a royalty-free, perpetual, irrevocable nonexclusive basis.
  5. I herewith confirm that the contact details saved in this system are those of the presenting author, who will be notified about the status of the abstract. The presenting author is responsible for informing the other authors about the status of the abstract. The submitting author may request to be copied on abstract correspondence.
  6. I understand that the presenting author must be a registered participant.
  7. The Organizers reserve the right to remove from publication and/or presentation an abstract which does not comply with the above.
  8. I understand that I must select a specific Theme, Topic and/or Sub-Topic for my abstract allocation.  Although the Committee will work hard to honor this selection, this cannot be guaranteed.  The Committee reserves the right to change the Theme, Topic or Sub-Topic under which the abstract was originally submitted.